AJP - Endo Cosmo Bio: Excellent Endocrine ELISAs
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab (March 9, 2004). doi:10.1152/ajpendo.00494.2003
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
287/1/E82    most recent
00494.2003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tietge, U. J. F.
Right arrow Articles by Bahr, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tietge, U. J. F.
Right arrow Articles by Bahr, M. J.
Submitted on November 3, 2003
Accepted on March 2, 2004

Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics

Uwe J. F. Tietge1*, Klaus H. W. Boker2, Michael P. Manns2, and Matthias J. Bahr2

1 Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany; Department of Medicine, Humboldt University, Charite Campus Mitte, Berlin, Germany
2 Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany

* To whom correspondence should be addressed. E-mail: u_tietge{at}yahoo.com.

Adiponectin is a novel adipocytokine negatively correlated with parameters of the metabolic syndrome, such as body mass index (BMI), body fat mass (BFM), and circulating insulin levels. Further, metabolic actions directly on the liver have been described. The aim of the present study was to characterize circulating adiponectin levels, hepatic turnover, and the association of adiponectin with key parameters of hepatic as well as systemic metabolism in cirrhosis, a catabolic disease. Circulating adiponectin levels and hepatic turnover were investigated in 20 patients with advanced cirrhosis. Hepatic hemodynamics (portal pressure, liver blood flow, hepatic vascular resistance, indocyanine green half-life), body composition, resting energy expenditure, hepatic free fatty acid and glucose turnover, circulating levels of hormones (catecholamines, insulin, glucagon) and proinflammatory cytokines (IL-1{beta}, TNF-{alpha}, IL-6) were also assessed. Circulating adiponectin increased dependent on the clinical stage in cirrhosis compared with controls (15.2 ± 1.7 vs. 8.2 ± 1.1 µg/ml, resp., p<0.01), while hepatic extraction decreased. Adiponectin was negatively correlated with parameters of hepatic protein synthesis (prothrombin time: r=-0.62, p=0.003, albumin: r=-0.72, p<0.001), but not with transaminases or parameters of lipid metabolism. In addition, circulating adiponectin increased with portal pressure (r=0.67, p=0.003), hepatic vascular resistance (r=0.60, p=0.008) and effective hepatic blood flow (ICG half-life: r=0.69, p=0.001). Adiponectin in cirrhosis was not correlated with BMI, BFM, parameters of energy metabolism, insulin levels, hepatic FFA and glucose turnover, and circulating proinflammatory cytokines. These results demonstrate that (i) adiponectin plasma levels in cirrhosis are significantly elevated, (ii) the liver is a major source of adiponectin extraction, and (iii) adiponectin levels in cirrhosis do not correlate with parameters of body composition or metabolism, but exclusively with reduced liver function and altered hepatic hemodynamics.




This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. J. Bahr, J. Ockenga, K. H. W. Boker, M. P. Manns, and U. J. F. Tietge
Elevated resistin levels in cirrhosis are associated with the proinflammatory state and altered hepatic glucose metabolism but not with insulin resistance
Am J Physiol Endocrinol Metab, August 1, 2006; 291(2): E199 - E206.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
Y. Nakano, S. Tajima, A. Yoshimi, H. Akiyama, M. Tsushima, T. Tanioka, T. Negoro, M. Tomita, and T. Tobe
A novel enzyme-linked immunosorbent assay specific for high-molecular-weight adiponectin
J. Lipid Res., July 1, 2006; 47(7): 1572 - 1582.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
C. Pagano, G. Soardo, W. Esposito, F. Fallo, L. Basan, D. Donnini, G. Federspil, L. A Sechi, and R. Vettor
Plasma adiponectin is decreased in nonalcoholic fatty liver disease
Eur. J. Endocrinol., January 1, 2005; 152(1): 113 - 118.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 2004 by the American Physiological Society.